Noopept vs Semax
Both are Russian-registered nootropics that raise neurotrophins in animals, but one is an oral dipeptide and the other an intranasal ACTH fragment. Neither is FDA-approved.
Short answer
Noopept and Semax both have human clinical data, so the deciding factor is what you want them for. Noopept suits someone focused on cognition and memory, while Semax is aimed at cognition, focus and neuroprotection. The headline human result for Noopept is benefit comparable to piracetam in small Russian trials in mild cognitive impairment; no placebo-controlled Western trial.
Noopept
A piracetam-analog dipeptide that raises NGF/BDNF in animals; the human data is small, single-country Russian trials — real but unreplicated to Western standards, and it's unapproved in the US.
Full Noopept evidence reviewSemax
A BDNF-raising ACTH(4-10) analog registered as a drug in Russia — but the human evidence is small, single-country and mostly uncontrolled.
Full Semax evidence reviewNoopept vs Semax: head to head
- FDA status / approved use
Noopept
Registered drug in Russia and nearby countries; not FDA-approved; no approved use in the US or EUSemax
Registered drug in Russia; not FDA-approved- Marketed for
Noopept
Cognition, memorySemax
Cognition, focus, neuroprotection- Outcome areas
Noopept
Cognitive function / memorySemax
Cognitive function / memory- Evidence grade
Noopept
Clinical dataSemax
Clinical data- How it works
Noopept
Raises the brain growth proteins NGF and BDNF in rat studiesSemax
ACTH(4-10) analog without hormonal activity that raises brain BDNF in animal studies- Route and dosing
Noopept
OralSemax
Intranasal- Headline human result
Noopept
Benefit comparable to piracetam in small Russian trials in mild cognitive impairment; no placebo-controlled Western trialSemax
Not established- Strongest evidence
Noopept
Neznamov, Neurosci Behav Physiol 2009Noopept evidence reviewPubMed 19234797Semax
Semax MND trial, Korsakov J 2007Semax evidence reviewPubMed 18379501- Key safety signal
Noopept
No long-term safety data; US products have unverified contentSemax
Robust and long-term human safety data are essentially absent- How it is obtained
Noopept
Sold gray-market as a research chemical; no approved or legitimately compounded human productSemax
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| Noopept | Semax | |
|---|---|---|
| FDA status / approved use | Registered drug in Russia and nearby countries; not FDA-approved; no approved use in the US or EU | Registered drug in Russia; not FDA-approved |
| Marketed for | Cognition, memory | Cognition, focus, neuroprotection |
| Outcome areas | Cognitive function / memory | Cognitive function / memory |
| Evidence grade | Clinical data | Clinical data |
| How it works | Raises the brain growth proteins NGF and BDNF in rat studies | ACTH(4-10) analog without hormonal activity that raises brain BDNF in animal studies |
| Route and dosing | Oral | Intranasal |
| Headline human result | Benefit comparable to piracetam in small Russian trials in mild cognitive impairment; no placebo-controlled Western trial | Not established |
| Strongest evidence | Neznamov, Neurosci Behav Physiol 2009Noopept evidence reviewPubMed 19234797 | Semax MND trial, Korsakov J 2007Semax evidence reviewPubMed 18379501 |
| Key safety signal | No long-term safety data; US products have unverified content | Robust and long-term human safety data are essentially absent |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
These two are near-twins on evidence quality: coherent animal mechanisms, with Noopept raising NGF and BDNF and Semax raising BDNF while touching dopamine, and human trials that are small, Russian, and comparator-controlled or uncontrolled rather than placebo-controlled. Noopept's most-cited human study compared it against piracetam, itself unapproved in the West; Semax's best-controlled human data is a placebo-controlled fMRI study measuring brain signals, not clinical outcomes. They have not been tested against each other, and both reach US buyers as unregulated research-only material.
Noopept fits if
Noopept is the one to read up on if oral dosing and the mild-cognitive-impairment literature are what you are tracking.
Semax fits if
Semax is the one if you care about the BDNF and dopamine mechanism, or about its stroke and neuroprotection use in Russia.
Noopept vs Semax: common questions
- Is either Noopept or Semax FDA-approved?
- No. Noopept is a registered drug in Russia and nearby countries; not FDA-approved; no approved use in the US or EU. Semax is a registered drug in Russia; not FDA-approved.
- Which has stronger human evidence, Noopept or Semax?
- Neither clearly. Both have human clinical data. The key source for Noopept is Neznamov, Neurosci Behav Physiol 2009; for Semax, it is Semax MND trial, Korsakov J 2007.
- What are the main safety concerns with Noopept and Semax?
- Noopept has no long-term safety data; US products have unverified content. With Semax, robust and long-term human safety data are essentially absent.
Key studies behind each
Noopept
- Ostrovskaya RU, et al. (2002). The original novel nootropic and neuroprotective agent noopept. Eksp Klin Farmakol. PubMed 12596521
- Ostrovskaya RU, Gudasheva TA, Voronina TA, et al. (2010). On the mechanism of noopept action: decrease in activity of stress-induced kinases and increase in expression of neutrophines. Eksp Klin Farmakol. PubMed 21395007
- Ostrovskaya RU, et al. (2008). Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection). Bull Exp Biol Med. PubMed 19145356
- Kondratenko RV, Derevyagin VI, Skrebitsky VG. (2010). Novel nootropic dipeptide Noopept increases inhibitory synaptic transmission in CA1 pyramidal cells. Neurosci Lett. PubMed 20382202
Semax
- Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. PubMed 16996037
- Tsai SJ. (2007). Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. PubMed 16996699
- Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, et al. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neurosci Behav Physiol. PubMed 15341218
- Serdiuk AV, et al. (2007). Open-label clinical trial of Semax in the treatment of motor neuron disease. Zh Nevrol Psikhiatr Im S S Korsakova. PubMed 18379501
The full evidence reviews
- Noopept: a potent Russian dipeptide nootropic with a thin clinical base
A proline-containing dipeptide analog of piracetam that raises NGF and BDNF in animal studies and is a registered drug in Russia. The mechanism is credible — but the human evidence is small, single-country, and unreplicated to Western standards.
Updated August 2026
- Semax: a real Russian nootropic with an under-tested evidence base
An ACTH(4-10)-derived heptapeptide that raises BDNF and is a registered drug in Russia. The mechanism is credible — but the human evidence is small, single-country, and mostly uncontrolled.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Noopept availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: ImmortalsLumoraLunaRxMavesMetoNava Health